Donald L. Hagan LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 32.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,027 shares of the biopharmaceutical company’s stock after selling 9,095 shares during the quarter. Donald L. Hagan LLC’s holdings in Pfizer were worth $698,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. NewSquare Capital LLC grew its holdings in shares of Pfizer by 0.4% during the second quarter. NewSquare Capital LLC now owns 60,418 shares of the biopharmaceutical company’s stock worth $1,976,000 after buying an additional 266 shares in the last quarter. Aevitas Wealth Management Inc. grew its stake in Pfizer by 1.7% in the second quarter. Aevitas Wealth Management Inc. now owns 15,916 shares of the biopharmaceutical company’s stock valued at $520,000 after purchasing an additional 269 shares in the last quarter. Cutter & CO Brokerage Inc. grew its stake in Pfizer by 2.0% in the second quarter. Cutter & CO Brokerage Inc. now owns 13,695 shares of the biopharmaceutical company’s stock valued at $448,000 after purchasing an additional 274 shares in the last quarter. Beaumont Asset Management L.L.C. grew its stake in Pfizer by 1.3% in the second quarter. Beaumont Asset Management L.L.C. now owns 21,244 shares of the biopharmaceutical company’s stock valued at $694,000 after purchasing an additional 276 shares in the last quarter. Finally, Dividend Assets Capital LLC grew its stake in Pfizer by 0.9% in the second quarter. Dividend Assets Capital LLC now owns 30,606 shares of the biopharmaceutical company’s stock valued at $1,001,000 after purchasing an additional 278 shares in the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.
In other news, Director Ronald E. Blaylock purchased 13,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at approximately $154,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.08% of the company’s stock.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period last year, the firm posted $0.80 EPS. On average, analysts predict that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a dividend of $0.38 per share. The ex-dividend date is Thursday, November 5th. This represents a $1.52 annualized dividend and a yield of 4.01%. Pfizer’s payout ratio is currently 51.53%.
A number of research firms have weighed in on PFE. ValuEngine downgraded Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Atlantic Securities downgraded Pfizer from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Royal Bank of Canada set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research note on Friday. SVB Leerink raised their price objective on Pfizer from $39.00 to $42.00 and gave the company a “market perform” rating in a research report on Wednesday, July 29th. Finally, Morgan Stanley raised their price objective on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $39.64.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: What is a SEC Filing?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.